EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers

Linda T H Godding iD, Elke M G J de Jong iD, Sylvia van Beugen iD, Antoinette I M van Laarhoven iD, Els van der Pool, Nanda J Olde, Debra Trampe, Hanna Niehues, Ilse van Ee, Annemarie Sluijmers, Robert Rissmann iD, Juul M P A van den Reek iD und 2 weitere

Experimental Dermatology · 2026

DOI: 10.1111/exd.70352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Linda T H Godding und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Skin Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Successful implementation of dermatological biomarkers depends on early understanding of clinical needs and adoption barriers. Yet, research on these factors as perceived by dermatological care providers (DCPs) is scarce and perspectives of patients are largely underexplored. This survey study among patients and DCPs assessed biomarker needs and adoption barriers and facilitators for five inflammatory skin diseases: psoriasis (PsO), atopic dermatitis (AD), hidradenitis suppurativa (HS), cutaneous lupus erythematosus (CLE) and chronic spontaneous urticaria (CSU). In total, the study population consisted of 591 patients and 99 DCPs. Across all skin diseases, both groups mainly prioritized a biomarker for prediction of therapeutic response, however, DCPs prioritized this substantially more often than patients, especially for PsO (79.8% vs. 31.3% resp.), AD (68.7% vs. 37.1% resp.) and HS (66.7% vs. 34.4% resp.). Notably, a biomarker for the prediction of the risk to develop comorbidities was prioritized relatively often by patients (7.0%–19.4%), whereas DCPs only substantially prioritized this for CLE (14.1%). To enhance implementation, patients must ideally be able to undergo biomarker collection nearby their homes (travel time < 1 h) with complete reimbursement. For DCPs it is important that the biomarker is well validated, non‐invasive and measurable during regular visits with preferably a short sampling time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersSkin DiseasesHumansFemalePsoriasisDermatitis, AtopicHidradenitis SuppurativaAdultSurveys and QuestionnairesLupus Erythematosus, CutaneousMaleUrticariaMiddle Aged

Stichwörter der Autor:innen

atopic dermatitischronic spontaneous urticariacutaneous lupus erythematosushidradenitis suppurativapsoriasis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands.
  • Lectoraat Human Communication Development, HAN University of Applied Sciences, Nijmegen, the Netherlands.
  • Psoriasispatiënten Nederland (PN), Nijkerk, the Netherlands.
  • Nationale vereniging voor mensen met lupus, APS, sclerodermie en MCTD (NVLE), Utrecht, the Netherlands.
  • Centre for Human Drug Research (CHDR), Leiden, the Netherlands.

ORCID-Profile: Linda T H Godding, Elke M G J de Jong, Sylvia van Beugen, Antoinette I M van Laarhoven, Robert Rissmann, Juul M P A van den Reek

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Godding, L. T. H., de Jong, E. M. G. J., van Beugen, S., van Laarhoven, A. I. M., van der Pool, E., Olde, N. J., Trampe, D., Niehues, H., van Ee, I., Sluijmers, A., Rissmann, R., van den Reek, J. M. P. A., Seyger, M. M. B., & Next Generation ImmunoDermatology Consortium (NGID) (2026). Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers. Experimental Dermatology. https://doi.org/10.1111/exd.70352

Vancouver

Godding LTH, de Jong EMGJ, van Beugen S, van Laarhoven AIM, van der Pool E, Olde NJ, et al. Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers. Experimental Dermatology. 2026. doi:10.1111/exd.70352

BibTeX
@article{Godding2026,
  author = {Godding, Linda T H and de Jong, Elke M G J and van Beugen, Sylvia and van Laarhoven, Antoinette I M and van der Pool, Els and Olde, Nanda J and Trampe, Debra and Niehues, Hanna and van Ee, Ilse and Sluijmers, Annemarie and Rissmann, Robert and van den Reek, Juul M P A and Seyger, Marieke M B and Next Generation ImmunoDermatology Consortium (NGID), Next Generation ImmunoDermatology Consortium (NGID)},
  title = {Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers},
  journal = {Experimental Dermatology},
  year = {2026},
  doi = {10.1111/exd.70352}
}
Kostenlos starten →